DiagnoCure Appoints Richard Bordeleau as Senior Advisor to the Board

Appointment Targeting Next Steps to Increasing Shareholder Value

QUEBEC CITY, Aug. 20, 2013 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF), a life sciences company developing and commercializing highvalue cancer diagnostic tests, today announced the appointment of Mr. Richard Bordeleau as Senior Advisor to the Company effective September 1, 2013. Mr. Bordeleau will act as an executive in residence and report directly to DiagnoCure’s board of directors. In collaboration with Company management, Mr. Bordeleau’s initial mandate will be to identify and implement short term actions aimed at increasing shareholder value, and also to evaluate mid to long term scenarios optimizing corporate value.

Mr. Bordeleau joins DiagnoCure, following a highly successful international career in the life sciences industry. During his term as President of Atrium Innovations from 2000 to 2007, the company experienced sustainable double-digit organic growth through direct sales combined with international license and distribution agreements, augmented by multiple accretive acquisitions in North America and Europe. Mr. Bordeleau also more recently contributed to the growth of BioCad Medical, positioning the company as a leader in CADCAM dentistry. BioCad Medical was purchased by Nobel Biocare 18 months after he joined the company. Mr. Bordeleau currently manages investments in start-up companies together with members of Anges Quebec, a network of business angels where he initiated investments in life sciences as responsible of the health and well-being sector.

“We are extraordinarily pleased that Mr. Bordeleau will be joining the DiagnoCure team. His strong track record of growing companies and creating value for shareholders is a powerful testament to his strength in successfully negotiating and closing international licensing and distribution agreements, and implementing value-creating acquisitions,” said Dr. Yves Fradet, Chairman of the Board.

“Reporting directly to the Board, Mr. Bordeleau’s business acumen will complement the scientific strengths of DiagnoCure’s management team and the clinical insight of our Chairman. The board has given Richard significant powers to act as executive in residence in the creation of both a long-term vision for success and a short-term improvement of shareholder value,” added Dr. Vincent Zurawski, DiagnoCure’s Lead Director.

About DiagnoCure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. Previstage^TM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on PCA3 to GenProbe, now a whollyowned subsidiary of Hologic Inc., operating as Hologic GenProbe, for the development and commercialization of a prostate cancer test, DiagnoCure’s proprietary molecular biomarker. Hologic GenProbe’s PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, please visit www.diagnocure.com.

Forwardlooking statements

This release contains forwardlooking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forwardlooking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure’s control. As a result, investors are cautioned not to place undue reliance on these forwardlooking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure’s most recent Annual Information Form under the heading “Risk Factors”. DiagnoCure undertakes no obligation to publicly update or revise any forwardlooking statements contained herein unless required by the applicable securities laws and regulations.

SOURCE DiagnoCure inc.